These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Tissue plasminogen activator is the best thrombolytic agent]. Bates E Arq Bras Cardiol; 1994 Jul; 63(1):57-8. PubMed ID: 7857215 [No Abstract] [Full Text] [Related]
3. [The prevention of reocclusion after thrombolysis in acute myocardial infarct: is tissue-type plasminogen activator really superior to streptokinase?]. Negrini M G Ital Cardiol; 1995 Apr; 25(4):511-5. PubMed ID: 7677921 [No Abstract] [Full Text] [Related]
4. Variable depletion of endogenous factor XII-dependent fibrinolytic activity following thrombolytic therapy of myocardial infarction and its relation to reinfarction. Kluft C; Munkvad S; Gram J; Jespersen J Agents Actions Suppl; 1992; 38 ( Pt 2)():299-304. PubMed ID: 1462835 [No Abstract] [Full Text] [Related]
5. Thrombolytic therapy for myocardial infarction: a perspective of clinical trialists. The GUSTO Investigators. Califf RM; Topol EJ Clin Cardiol; 1992 Mar; 15(3):143-4. PubMed ID: 1551260 [No Abstract] [Full Text] [Related]
6. [Thrombolytic therapy of acute myocardial infarction]. Chen JL Zhonghua Yi Xue Za Zhi; 2005 Jan; 85(1):69-70. PubMed ID: 15808085 [No Abstract] [Full Text] [Related]
8. New developments in thrombolytic therapy. Collen D; Gold HK Adv Exp Med Biol; 1990; 281():333-54. PubMed ID: 2129372 [TBL] [Abstract][Full Text] [Related]
9. Thrombolytic therapy of myocardial infarction--it's time for science, not marketing: the perspective of a practicing cardiologist. Vogel JH Clin Cardiol; 1991 Jul; 14(7):548. PubMed ID: 1810292 [No Abstract] [Full Text] [Related]
10. ISIS-3 and GISSI-2: no survival advantage with tissue plasminogen activator over streptokinase, but a significant excess of strokes with tissue plasminogen activator in both trials. Collins R; Peto R; Parish S; Sleight P Am J Cardiol; 1993 May; 71(12):1127-30. PubMed ID: 8475887 [No Abstract] [Full Text] [Related]
11. [Thrombolytic therapy of acute myocardial infarction]. Chen HZ Zhonghua Nei Ke Za Zhi; 1993 Jan; 32(1):5-6. PubMed ID: 8404321 [No Abstract] [Full Text] [Related]
12. Is the use of t-PA as compared with streptokinase cost effective? Rose EA N Engl J Med; 1995 Oct; 333(15):1009; author reply 1010. PubMed ID: 7666904 [No Abstract] [Full Text] [Related]
13. [Thrombolytic therapy for myocardial infarction in oral anticoagulation]. Pizzulli L; Lüderitz B Dtsch Med Wochenschr; 1996 Mar; 121(13):424. PubMed ID: 8681737 [No Abstract] [Full Text] [Related]
14. Thrombolytic therapy for myocardial infarction. Guerci AD Md Med J; 1990 Apr; 39(4):377-81. PubMed ID: 2110282 [TBL] [Abstract][Full Text] [Related]
15. More on the GUSTO Trial. Lomaestro BM Ann Intern Med; 1994 Nov; 121(10):818-9. PubMed ID: 7944069 [No Abstract] [Full Text] [Related]
16. Is the use of t-PA as compared with streptokinase cost effective? Armentano R; Favaloro RG N Engl J Med; 1995 Oct; 333(15):1009-10. PubMed ID: 7666905 [No Abstract] [Full Text] [Related]
17. [Thrombolytic therapy in acute myocardial infarction. Mechanism of action and treatment considerations]. Roguin A; Manaster J; Roguin N Harefuah; 1993 Jun; 124(12):770-5. PubMed ID: 8375772 [No Abstract] [Full Text] [Related]
18. Second-dose thrombolytic following myocardial infarction. Furniss SS; Millar RN; Commerford PJ S Afr Med J; 1997 Feb; 87(2):179, 182. PubMed ID: 9107231 [No Abstract] [Full Text] [Related]
19. [Thrombolytic treatment of acute myocardial infarct. 1]. Soares-Costa JT; Soares-Costa TJ; Gabriel HM Acta Med Port; 1998 May; 11(5):409-19. PubMed ID: 9951051 [TBL] [Abstract][Full Text] [Related]
20. [The Medical Products Agency and thrombolytic therapy in acute myocardial infarction]. Rasmussen K Tidsskr Nor Laegeforen; 1994 Jun; 114(17):2033-4. PubMed ID: 8079341 [No Abstract] [Full Text] [Related] [Next] [New Search]